This information card provides information on the multiple significant drug interactions between TB medications; specifically, INH, rifampin, and other medications and the effect of the interaction. It also provides information on food interactions with TB drugs.
This fact sheet provides information on tuberculin skin testing. It explains how to interpret tuberculin skin test (TST) results, including special considerations.
This pocket-sized card for clinicians provides information on identifying those at risk for TB. The resource also includes content on latent TB infection testing, diagnosis, and treatment in adults.
This fact sheet is a step-by-step guideline discussing the supplies required, limitations and precautions, pharmacokinetics, proper storage, and accurate placement for injection of Amikacin with picture guides. The reverse side features a table covering Amikacin, Streptomycin, and Capreomycin, including information regarding drug information, dosing, side effects, monitoring, contraindications and use in renal disease.
This pocket guide is intended to assist clinicians in managing patients with HIV and LTBI, and drug-susceptible pulmonary TB disease. The guide includes signs and symptoms, adult dosing, dosage forms, drug-drug interactions, side effects, and patient counseling points.
The Latent TB Infection (LTBI) Treatment Fact Sheet Series is designed to complement patient education delivered by healthcare professionals. Each sheet provides patients with a written reminder of their treatment regimen, medication side effects, actions to take if side effects do occur, tips to help remain adherent to the medication, and instructions in the event a dose of medication is missed.
This pocket card provides information on the treatment of drug-susceptible TB disease. The pocket card is adapted from the 2016 Official American Thoracic Society, Centers for Disease Control and Prevention, Infectious Disease Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
This poster is intended to encourage health care workers to advise clients that if conditions of tuberculosis (TB) symptoms last more than 2-3 weeks, to avoid group settings and see a medical provider immediately.
This report analyses the factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. Detailed pricing profiles of key DR-TB drugs are also provided.
This Public Health Grand Rounds session discusses how more patients can benefit from advances in diagnostic and treatment options, resulting in an overall reduction in morbidity from MDR TB. The session also explores the role of CDC, WHO, and other partners in combating the public health epidemic.
